三阴性转移性乳腺癌（TN mBC）在乳腺癌领域内是最具挑战性的情况，尽管我们在过去几年看到了一系列药物的可用性和生存延长方面的巨大进展，但它仅略受影响。然而，虽然化疗仍然是TN mBC管理的主要支柱，但在过去几年中，已开发了几种新型有效药物，并在临床实践中提供。在此框架内，由17名广受国际认可的乳腺癌肿瘤学家和42名在当地卫生中心工作的肿瘤学家组成的科学委员会，针对TN mBC管理的 26个高优先级声明，包括灰色领域进行了讨论。采用基于改进的德尔菲方法的结构化方法进行调查和名义小组技术捕捉意见和偏好，研究意大利肿瘤学界对TN mBC管理的看法。该小组生成了一组有关诊断和分期方法，PD-L1阳性/基因BRCA（gBRCA）野生型，PD-L1阳性/gBRCA突变型，PD-L1阴性/gBRCA野生型和PD-L1阴性/gBRCA突变型TN mBC的一线和二线治疗的优先考虑/共识声明。专家组对最相关和/或意外的结果进行了批判性和全面的讨论，并提出了可能对未达成共识阈值的声明的解释。版权所有2023年作者。由Elsevier Ltd.出版。保留所有权利。

Triple-negative (TN) metastatic breast cancer (mBC) represents the most challenging scenario withing mBC framework, and it has been only slightly affected by the tremendous advancements in terms of drug availability and survival prolongation we have witnessed in the last years for advanced disease. However, although chemotherapy still represents the mainstay of TN mBC management, in the past years, several novel effective agents have been developed and made available in the clinical practice setting. Within this framework, a panel composed of a scientific board of 17 internationally recognized breast oncologists and 42 oncologists working within local spoke centers, addressed 26 high-priority statements, including grey areas, regarding the management of TN mBC. A structured methodology based on a modified Delphi approach to administer the survey and the Nominal Group Technique to capture perceptions and preferences on the management of TN mBC within the Italian Oncology community were adopted. The Panel produced a set of prioritized considerations/consensus statements reflecting the Panel position on diagnostic and staging approach, first-line and second-line treatments of PD-L1-positive/germline BRCA (gBRCA) wild-type, PD-L1-positive/gBRCA mutated, PD-L1-negative/gBRCA wild-type and PD-L1-negative/gBRCA mutated TN mBC. The Panel critically and comprehensively discussed the most relevant and/or unexpected results and put forward possible interpretations for statements not reaching the consensus threshold.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.